These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2574 related articles for article (PubMed ID: 26030518)

  • 21. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
    Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
    Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
    Mayer EL; Fesl C; Hlauschek D; Garcia-Estevez L; Burstein HJ; Zdenkowski N; Wette V; Miller KD; Balic M; Mayer IA; Cameron D; Winer EP; Ponce Lorenzo JJ; Lake D; Pristauz-Telsnigg G; Haddad TC; Shepherd L; Iwata H; Goetz M; Cardoso F; Traina TA; Sabanathan D; Breitenstein U; Ackerl K; Metzger Filho O; Zehetner K; Solomon K; El-Abed S; Theall KP; Lu DR; Dueck A; Gnant M; DeMichele A
    J Clin Oncol; 2022 Feb; 40(5):449-458. PubMed ID: 34995105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Gelmon KA; Cristofanilli M; Rugo HS; DeMichele AM; Joy AA; Castrellon A; Sleckman B; Mori A; Theall KP; Lu DR; Huang X; Bananis E; Finn RS; Slamon DJ
    Breast J; 2020 Mar; 26(3):368-375. PubMed ID: 31448513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
    Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
    Harbeck N; Iyer S; Turner N; Cristofanilli M; Ro J; André F; Loi S; Verma S; Iwata H; Bhattacharyya H; Puyana Theall K; Bartlett CH; Loibl S
    Ann Oncol; 2016 Jun; 27(6):1047-1054. PubMed ID: 27029704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
    Bidard FC; Hardy-Bessard AC; Dalenc F; Bachelot T; Pierga JY; de la Motte Rouge T; Sabatier R; Dubot C; Frenel JS; Ferrero JM; Ladoire S; Levy C; Mouret-Reynier MA; Lortholary A; Grenier J; Chakiba C; Stefani L; Plaza JE; Clatot F; Teixeira L; D'Hondt V; Vegas H; Derbel O; Garnier-Tixidre C; Canon JL; Pistilli B; André F; Arnould L; Pradines A; Bièche I; Callens C; Lemonnier J; Berger F; Delaloge S;
    Lancet Oncol; 2022 Nov; 23(11):1367-1377. PubMed ID: 36183733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
    Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ
    Ann Oncol; 2019 Sep; 30(9):1514-1520. PubMed ID: 31250880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
    Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
    Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.
    Xu B; Zhang Q; Zhang P; Hu X; Li W; Tong Z; Sun T; Teng Y; Wu X; Ouyang Q; Yan X; Cheng J; Liu Q; Feng J; Wang X; Yin Y; Shi Y; Pan Y; Wang Y; Xie W; Yan M; Liu Y; Yan P; Wu F; Zhu X; Zou J;
    Nat Med; 2021 Nov; 27(11):1904-1909. PubMed ID: 34737452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
    Llombart-Cussac A; Pérez-García JM; Bellet M; Dalenc F; Gil-Gil M; Ruíz-Borrego M; Gavilá J; Sampayo-Cordero M; Aguirre E; Schmid P; Marmé F; Di Cosimo S; Gligorov J; Schneeweiss A; Albanell J; Zamora P; Wheatley D; Martínez-de Dueñas E; Amillano K; Malfettone A; Cortés J;
    JAMA Oncol; 2021 Dec; 7(12):1791-1799. PubMed ID: 34617955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
    Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
    Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
    Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
    Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
    Albanell J; Martínez MT; Ramos M; O'Connor M; de la Cruz-Merino L; Santaballa A; Martínez-Jañez N; Moreno F; Fernández I; Alarcón J; Virizuela JA; de la Haba-Rodríguez J; Sánchez-Rovira P; González-Cortijo L; Margelí M; Sánchez-Muñoz A; Antón A; Casas M; Bezares S; Rojo F
    Eur J Cancer; 2022 Jan; 161():26-37. PubMed ID: 34902765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
    Dawood S; Chiu JW; Huang CS; Nag S; Sookprasert A; Yap YS; Md Yusof M
    Curr Med Res Opin; 2020 Aug; 36(8):1363-1373. PubMed ID: 32544344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
    Rugo HS; Turner NC; Finn RS; Joy AA; Verma S; Harbeck N; Masuda N; Im SA; Huang X; Kim S; Sun W; Iyer S; Schnell P; Bartlett CH; Johnston S
    Eur J Cancer; 2018 Sep; 101():123-133. PubMed ID: 30053671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Oliveira M; Rugo HS; Howell SJ; Dalenc F; Cortes J; Gomez HL; Hu X; Toi M; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Nowecki Z; Park YH; Sohn JH; Tokunaga E; Yousef S; Zhukova L; Fulford M; Andrews H; Wadsworth I; D'Cruz C; Turner NC;
    Lancet Oncol; 2024 Sep; 25(9):1231-1244. PubMed ID: 39214106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
    Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
    J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
    du Rusquec P; Palpacuer C; Campion L; Patsouris A; Augereau P; Gourmelon C; Robert M; Dumas L; Caroline F; Campone M; Frenel JS
    Breast Cancer Res Treat; 2018 Apr; 168(2):559-566. PubMed ID: 29247442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 129.